Contact Us | Lab News | Lab Members | Publications
Primary Research Focus
At the clinical onset of type 1 diabetes (T1D), human patients still have some functional beta cell mass remaining. If we could control autoimmunity against beta cells, T1D may be cured by increasing the remaining β cell mass to restore normoglycemia. The goal of current research in my laboratory is to develop therapeutic approaches to treating T1D by ameliorating autoimmunity and by promoting beta cell survival and regeneration.
Our current research interests are focused on:
- Investigating human beta cell survival and regeneration in humanized mouse models with human islet grafts.
- Identifying non-coding RNAs as biomarkers to detect beta cell loss and to monitor the outcome of treatment in nonobese diabetic (NOD) mice, a mouse model of human T1D and in humanized mice with human islet grafts.
- Understanding therapeutically relevant mechanisms of modulating the inflammatory response and stimulating beta cell regeneration in NOD mice.
- Targeting G protein-coupled receptors using small molecular agonists alone and in combination with dipeptidyl peptidase-4 (DPP-IV) inhibitors to stimulate beta cell regeneration.
Phone: (605) 312-6030